[go: up one dir, main page]

WO2023177841A3 - Produits de combinaison permettant d'atténuer le mésusage de stimulants du système nerveux central - Google Patents

Produits de combinaison permettant d'atténuer le mésusage de stimulants du système nerveux central Download PDF

Info

Publication number
WO2023177841A3
WO2023177841A3 PCT/US2023/015455 US2023015455W WO2023177841A3 WO 2023177841 A3 WO2023177841 A3 WO 2023177841A3 US 2023015455 W US2023015455 W US 2023015455W WO 2023177841 A3 WO2023177841 A3 WO 2023177841A3
Authority
WO
WIPO (PCT)
Prior art keywords
misuse
effective amount
mitigate
nervous system
combination products
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2023/015455
Other languages
English (en)
Other versions
WO2023177841A2 (fr
Inventor
Michael PRESTI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2023177841A2 publication Critical patent/WO2023177841A2/fr
Publication of WO2023177841A3 publication Critical patent/WO2023177841A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne un procédé permettant de réduire l'utilisation concomitante de médicaments stimulants et d'alcool. Dans un exemple, le procédé consiste à administrer au sujet un produit de combinaison qui comprend une quantité efficace d'un ou de plusieurs médicaments stimulants, et une quantité efficace d'un ou de plusieurs inhibiteurs de l'aldéhyde déshydrogénase (ALDI), afin de fournir les effets souhaités du médicament stimulant conjointement avec une substance qui empêche ou dissuade le sujet de consommer de l'alcool de manière concomitante, ce qui permet de réduire le mésusage de médicaments stimulants en association avec l'alcool. Sont également divulgués des produits de combinaison qui comprennent la quantité efficace d'un ou plusieurs médicaments stimulants et la quantité efficace d'un ou plusieurs ALDI.
PCT/US2023/015455 2022-03-18 2023-03-17 Produits de combinaison permettant d'atténuer le mésusage de stimulants du système nerveux central Ceased WO2023177841A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263321221P 2022-03-18 2022-03-18
US63/321,221 2022-03-18

Publications (2)

Publication Number Publication Date
WO2023177841A2 WO2023177841A2 (fr) 2023-09-21
WO2023177841A3 true WO2023177841A3 (fr) 2023-10-19

Family

ID=88024197

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/015455 Ceased WO2023177841A2 (fr) 2022-03-18 2023-03-17 Produits de combinaison permettant d'atténuer le mésusage de stimulants du système nerveux central

Country Status (1)

Country Link
WO (1) WO2023177841A2 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090281112A1 (en) * 2008-05-08 2009-11-12 Fabre-Kramer Pharmaceuticals, Inc. Adatanserin and metabolites thereof for treatment of attention deficit disorder, anxiety, depression, sexual dysfunction, and other disorders
US20100291205A1 (en) * 2007-01-16 2010-11-18 Egalet A/S Pharmaceutical compositions and methods for mitigating risk of alcohol induced dose dumping or drug abuse
US20160213628A1 (en) * 2013-09-09 2016-07-28 Nova Southeastern University Deterring abuse of pharmaceutical products and alcohol
US20190231719A1 (en) * 2018-01-26 2019-08-01 Michael Presti Combination treatments for opioid crisis

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100291205A1 (en) * 2007-01-16 2010-11-18 Egalet A/S Pharmaceutical compositions and methods for mitigating risk of alcohol induced dose dumping or drug abuse
US20090281112A1 (en) * 2008-05-08 2009-11-12 Fabre-Kramer Pharmaceuticals, Inc. Adatanserin and metabolites thereof for treatment of attention deficit disorder, anxiety, depression, sexual dysfunction, and other disorders
US20160213628A1 (en) * 2013-09-09 2016-07-28 Nova Southeastern University Deterring abuse of pharmaceutical products and alcohol
US20190231719A1 (en) * 2018-01-26 2019-08-01 Michael Presti Combination treatments for opioid crisis

Also Published As

Publication number Publication date
WO2023177841A2 (fr) 2023-09-21

Similar Documents

Publication Publication Date Title
Bray et al. Update on obesity pharmacotherapy
Cunha et al. Pharmacological modulation of secondary mediator systems–cyclic AMP and cyclic GMP–on inflammatory hyperalgesia
Valenti et al. Biphasic effect of nitric oxide on testosterone and cyclic GMP production by purified rat Leydig cells cultured in vitro
Dehesa et al. Treatment of inflammatory nail disorders
McAlindon et al. Nutritional factors and osteoarthritis: recent developments
Cappuzzo Treatment of postherpetic neuralgia: focus on pregabalin
Parenti et al. Harpagophytum procumbens extract potentiates morphine antinociception in neuropathic rats
Nugerahani et al. In vivo evaluation of Monascus-fermented durian seed for antidiabetic and antihypercholesterol agent
CA2699521A1 (fr) Procedes et compositions connexes utilisant des flavonoides et des indanes specifiques afin de reduire le poids et de limiter l&#39;activite de la lipase, de l&#39;.alpha.-amylase et de l&#39;.alpha.-glucosidase chez les mammiferes
Pacifici et al. Immunomodulating activity of MDMA
Koo et al. Inulin stimulates NO synthesis via activation of PKC-α and protein tyrosine kinase, resulting in the activation of NF-κB by IFN-γ-primed RAW 264.7 cells
WO2023177841A3 (fr) Produits de combinaison permettant d&#39;atténuer le mésusage de stimulants du système nerveux central
Retnowati et al. The stability and irritability study of the chitosan–aloe vera spray gel as wound healing
Grogan et al. The mechanism of cannabichromene and cannabidiol alone versus in combination in the alleviation of arthritis-related inflammation
Borja-Oliveira Alcohol-medication interactions: the acetaldehyde syndrome
Isadiartuti et al. Uji efektifitas sediaan gel antiseptik tangan yang mengandung etanol dan triklosan
Prakoeswa et al. The Role of Moisturizer Containing Anti‐inflammatory on Skin Hydration in Mild‐Moderate Atopic Dermatitis Patients
Ramanjooloo et al. α-Glucosidase inhibitory activity of marine sponges collected in Mauritius waters
Enos et al. Treatment of extensive elastosis perforans serpiginosa with acitretin in a man with Down syndrome.
Luo et al. Selinexor Reduces the Immunosuppressive Properties of Macrophages and Synergizes with CD19 CAR-T Cells Against B-Cell Lymphoma
Penning et al. Caffeinated drinks, alcohol consumption and hangover severity
EP2428117A1 (fr) Action anti-inflammatoire de phénéthyl isothiocyanate (PEITC) et préparation de graines de Barbarea verna contenant ce composé
Catalli et al. Inhibitory effects of resveratrol on human mast cell degranulation, cytokine, chemokine and leukotriene release
DE10133786A1 (de) Verwendung von Thrombin-Inhibitoren zur Behandlung von Arthritis
Kartini et al. Wound healing activity of aucubin on hyperglycemic rat

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23771436

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 24/01/2025)

122 Ep: pct application non-entry in european phase

Ref document number: 23771436

Country of ref document: EP

Kind code of ref document: A2